Effective dose of remimazolam combined with different doses butorphanol inhibiting response to cervical dilation during artificial abortion: A randomized dose-finding clinical study

Abstract

Abstract The purpose was to determine the effective dose of remimazolam (RMZ) combined with different doses butorphanol inhibiting response to cervical dilation during artificial abortion. This is a prospective, randomized, and double-blind study. Sixty-one female patients were randomly assigned to Group B10 (31 patients) and Group B15 (30 patients). All patients were given RMZ 5 min after an intravenous (IV) administration of butorphanol 10 μg/kg (Group B10) and 15 μg/kg (Group B15). According to the pre-experiment, the first dose of RMZ in the first patient was 0.35 mg/kg, and the adjacent geometric dose ratio was 0.9. The centered isotonic regression was performed to determine the ED50 and ED90 of RMZ and their corresponding 90% confidence interval (CI). The total RMZ dose administered, recovery time, and anesthesia-related adverse events were all recorded. The recovery time in Group B10 was significantly shorter than in Group B15. The incidence of post-operative nausea and vomiting (PONV) in the B10 and B15 groups was 3.2% and 16.7%, respectively. Therefore, to enhance the sedative effect of RMZ, the recommended dose of butorphanol is 10 μg/kg, and the ED50 and ED90 of the RMZ during painless artificial abortion were 0.263 and 0.331 mg/kg, respectively.